Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: February 4, 2021
Reporting Period: Fourth quarter and full year ended December 31, 2020.
Key Financial Metrics
This filing serves as a notification of the issuance of an Earnings Press Release and supplemental information. The specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not contained within the text of this Form 8-K. These figures are located in the referenced exhibits (Exhibit 99.1 and Exhibit 99.2) which are incorporated by reference but not reproduced in this document.
Material Changes
The filing does not detail specific material changes or comparative financial data within its text. It directs investors to the Earnings Press Release for the announcement of financial results for the fourth quarter and full year of 2020.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, risk factors, and contingencies are not explicitly stated in this filing. The document indicates that such information is available in the press release and supplemental website information furnished as exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 4, 2021) for specific Q4 and full-year 2020 financial results.
- Access Exhibit 99.2 for supplemental information posted on the company website (www.bms.com).
- Verify the trading status of registered securities: Common Stock (BMY), 1.000% Notes due 2025 (BMY25), 1.750% Notes due 2035 (BMY35), and Celgene Contingent Value Rights (CELG RT).
- Confirm that the filing does not contain the actual financial tables, requiring cross-reference to the external exhibits for data analysis.